Grant: Engage Grants Program
University of Waterloo
$25,000.00
Development of mathematical modelling tools for comparison of biosimilars
FY 2017-18
Summary
Subsequent entry pharmaceutical (also known as off-patent or generic) drug manufacturing can providesignificant savings to patients and healthcare systems. To enter the market, a subsequent entry pharmaceuticaldrug must be demonstrated to be as therapeutically effective as the original patented version. Demonstrationsof equivalence are relatively straightforward for most traditional small-molecule drugs, as molecular replicas ofthe original can be readily generated by chemical synthesis. In contrast, demonstration of equivalence of thenew class of biologic drugs (such as therapeutic antibodies) is not possible because these drugs are producedfrom diverse biological sources (such as living cells) which results in considerable variability in their structure(and hence chemistry) during manufacturing, even between production batches. As a consequence, subsequententry biologics cannot be compared to the original patented biologic solely on the basis of structural andchemical features; and are therefore, often referred to as biosimilars rather than generics. The Canadianpharmaceutical company Apobiologix (Division of ApoPharma USA, Inc; a member of the Apotex Group ofCompanies) is exploring new approaches for verifying the similarity of its new subsequent entry biosimilar toa an the clinically approved breast-cancer biologic known as trastuzamab (marketed as Herceptin). They areseeking to characterize cellular responses of trastuzumab and their biosimilar to identify similarities anddifferences in drug action. As part of that characterization, the proposed research involves development of acomputational modelling framework to interpret data from experiments comparingthe effects of these drugs onbiochemical response networks in breast cancer cells. Insights from these modeling analyses are expected toreduce the time for development efforts of Apobiologix's trastuzamab biosimilar to reach the market, bringingcost-savings to breast cancer patients and healthcare systems earlier rather than later.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
515369-2017
Name nom
Ingalls, Brian
Department département
Applied Mathematics
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
2957
Research subject group en
Applied mathematics
Research subject group fr
Mathématiques appliquées
Research subject en
Mathematical biology andphysiology
Research subject fr
Mathématiques de la biologie et de la physiologie
Partie
1
Nb partie
1
Application title
Development of mathematical modelling tools for comparison of biosimilars
Keyword
NSERC
Application summary
Subsequent entry pharmaceutical (also known as off-patent or generic) drug manufacturing can providesignificant savings to patients and healthcare systems. To enter the market, a subsequent entry pharmaceuticaldrug must be demonstrated to be as therapeutically effective as the original patented version. Demonstrationsof equivalence are relatively straightforward for most traditional small-molecule drugs, as molecular replicas ofthe original can be readily generated by chemical synthesis. In contrast, demonstration of equivalence of thenew class of biologic drugs (such as therapeutic antibodies) is not possible because these drugs are producedfrom diverse biological sources (such as living cells) which results in considerable variability in their structure(and hence chemistry) during manufacturing, even between production batches. As a consequence, subsequententry biologics cannot be compared to the original patented biologic solely on the basis of structural andchemical features; and are therefore, often referred to as biosimilars rather than generics. The Canadianpharmaceutical company Apobiologix (Division of ApoPharma USA, Inc; a member of the Apotex Group ofCompanies) is exploring new approaches for verifying the similarity of its new subsequent entry biosimilar toa an the clinically approved breast-cancer biologic known as trastuzamab (marketed as Herceptin). They areseeking to characterize cellular responses of trastuzumab and their biosimilar to identify similarities anddifferences in drug action. As part of that characterization, the proposed research involves development of acomputational modelling framework to interpret data from experiments comparingthe effects of these drugs onbiochemical response networks in breast cancer cells. Insights from these modeling analyses are expected toreduce the time for development efforts of Apobiologix's trastuzamab biosimilar to reach the market, bringingcost-savings to breast cancer patients and healthcare systems earlier rather than later.